Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit it ...

Abrocitinib is under clinical development by Pfizer and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders have a 20% phase ...

Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, ...

However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...

(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...

Pfizer PFE-0.49%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.95%decrease; red down pointing triangle for 2.50 billion ...

With Staquis and Cibinqo, Pfizer is empowering patients with effective options ... Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward. At the 2025 ...

Here’s what you need to know heading into Day Two. Pfizer announced plans to go “all in” on its experimental obesity drug danuglipron. Calling it “danu” for short, CEO Albert Bourla said late-stage ...